Travere Therapeutics, Inc.
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Travere Therapeutics is a biopharmaceutical company that develops and markets therapies for rare kidney diseases, including treatments for IgA nephropathy and other rare renal conditions.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Dube Eric MCHIEF EXECUTIVE OFFICER | Sell | $6.57M | 101,691at $64.59 | Sep 17, 2026 |
| Dube Eric MCHIEF EXECUTIVE OFFICER | Sell | $6.31M | 99,716at $63.26 | Sep 16, 2026 |
| Dube Eric MCHIEF EXECUTIVE OFFICER | Sell | $6.12M | 96,125at $63.64 | Sep 16, 2026 |
| Heerma PeterEVP, CHIEF COMMERCIAL OFFICER | Sell | $5.92M | 93,604at $63.25 | Sep 16, 2026 |
| Heerma PeterEVP, CHIEF COMMERCIAL OFFICER | Sell | $5.04M | 79,113at $63.65 | Sep 16, 2026 |
| Heerma PeterEVP, CHIEF COMMERCIAL OFFICER | Sell | $4.46M | 71,938at $62.05 | Sep 15, 2026 |
| ROTE WILLIAM E.Chief Research Officer | Sell | $4.11M | 65,104at $63.12 | Sep 16, 2026 |
| ROTE WILLIAM E.Chief Research Officer | Sell | $3.96M | 63,907at $61.99 | Sep 15, 2026 |
| Dube Eric MCHIEF EXECUTIVE OFFICER | Sell | $3.94M | 63,498at $61.99 | Sep 15, 2026 |
| ROTE WILLIAM E.Chief Research Officer | Sell | $3.04M | 47,746at $63.61 | Sep 16, 2026 |
| ROTE WILLIAM E.Chief Research Officer | Sell | $1.82M | 29,021at $62.66 | Sep 15, 2026 |
| Dube Eric MCHIEF EXECUTIVE OFFICER | Sell | $1.80M | 28,796at $62.66 | Sep 15, 2026 |
| Heerma PeterEVP, CHIEF COMMERCIAL OFFICER | Sell | $1.72M | 27,421at $62.59 | Sep 15, 2026 |
| Cline Christopher R.CHIEF FINANCIAL OFFICER | Sell | $1.70M | 27,473at $62.00 | Sep 15, 2026 |
| Inrig JulaEVP, Head of R&D & CMO | Sell | $1.57M | 25,390at $62.02 | Sep 15, 2026 |
| REED ELIZABETH EChief Legal Officer and GC | Sell | $1.36M | 21,926at $62.03 | Sep 15, 2026 |
| Cline Christopher R.CHIEF FINANCIAL OFFICER | Sell | $1.30M | 20,735at $62.61 | Sep 15, 2026 |
| Inrig JulaEVP, Head of R&D & CMO | Sell | $1.08M | 17,284at $62.62 | Sep 15, 2026 |
| REED ELIZABETH EChief Legal Officer and GC | Sell | $869K | 13,874at $62.63 | Sep 15, 2026 |
| Heerma PeterEVP, CHIEF COMMERCIAL OFFICER | Sell | $539K | 8,282at $65.07 | Sep 17, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable TVTX activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.